ライフサイエンスコーパス: human insulin

1 ecular weight guests such as proteins (e.g., human insulin).

2 program to switch patients from analogue to human insulin.

3 y profiles compared with that of recombinant human insulin.

4 t in birds and fish) augments the potency of human insulin.

5 gic and saturating concentrations of regular human insulin.

6 ein can be used to extend the time action of human insulin.

7 nmodified peptides as complex as recombinant human insulin.

8 or tetraplex structures in the expression of human insulin.

9 de, has similar receptor binding affinity to human insulin.

10 1.35 A, is essentially identical to that of human insulin.

11 sulin signaling and in vivo bioactivities to human insulin.

12 -glucose abolished the stimulatory effect of human insulin (1 nM, 8 h) on L-[3H]leucine incorporation

13 was achieved by administering a recombinant human insulin a few hours after Albulin injection in mic

14 ted transgenic potato plants that synthesize human insulin, a major insulin-dependent diabetes mellit

15 We showed previously that ingested human insulin activates the insulin/IGF-1 signaling path

16 of action of [N(epsilon)-palmitoyl Lys(B29)] human insulin administered intravenously was nearly twic

17 hniques [recombinant human (r-human) and its human insulin analog (LysPro)].

18 A recombinant monomeric human insulin analog, which does not bind to the insulin

19 eater than that of an analogous single-chain human insulin analog.

20 hesized and evaluated a methylene thioacetal human insulin analogue (SCS-Ins).

21 ls is to screen the amyloid-forming proteins human insulin and beta(2)-microglobulin for segments tha

22 nstrated that the presence of high levels of human insulin and bovine insulin does not interfere with

23 n glucose stimulation of the implanted mice, human insulin and C-peptide are detected in sera at leve

24 was assessed by measuring the production of human insulin and C-peptide over a period of 3-15 months

25 In vivo function was assessed by measuring human insulin and C-peptide production, and by the abili

26 ncreatic beta cells where it is processed to human insulin and CpepSfGFP.

27 f Chinese hamster ovary cells expressing the human insulin and EGF receptors resulted in a time-depen

28 The effects of human insulin and elevated D-glucose on L-arginine trans

29 imultaneous, direct quantification of intact human insulin and five insulin analogs in human plasma.

30 Human insulin and its current therapeutic analogs all sh

31 o islet-like structures capable of producing human insulin and maintaining normoglycemia.

32 glycemic control similar to that of premixed human insulin and may provide tighter glycemic control t

33 ogical efficacy, we used UTMD to deliver RIP-human insulin and RIP-hexokinase I plasmids to islets of

34 t insulin with 40 to 100% of the activity on human insulin, and all mAbs bind proinsulin.

35 is folded in the ER, exported, converted to human insulin, and secreted.

36 venously was nearly twice that of unmodified human insulin, and the plasma half-life was nearly seven

37 eak daf-2 mutants, suggesting that INS-1 and human insulin antagonize DAF-2 insulin-like signaling.

38 t the potency and thermodynamic stability of human insulin are enhanced in concert by substitution of

39 the C-terminal prolyl and lysyl residues of human insulin are inverted, and protamine that is used a

40 ssignment of paired cysteine residues, using human insulin as a model protein.

41 , we characterize the aggregation process of human insulin at acidic pH in the presence of sulfate io

42 ate of the protein, the crystal structure of human insulin at pH 2.1 has been determined to 1.6 A res

43 two class III VNTR constructs linked to the human insulin basal promoter or SV40 heterologous promot

44 educed three out of four disulfide bridges), human insulin, bovine core histones, and human alpha-syn

45 e investigated the fibrillation of monomeric human insulin by monitoring changes in CD, attenuated to

46 With this gene, the secretion of human insulin by the exocrine pancreas normalized elevat

47 This paper describes the binding of human insulin by the synthetic receptor cucurbit[7]uril

48 nsulin derivative octanoyl-N(epsilon)-LysB29-human insulin (C8-HI).

49 insulin/IGF-1 signaling pathway by ingested human insulin can alter NF-kappaB-dependent immunity, an

50 We show here that human insulin can be cocrystallized at preselected ratio

51 Mutations in human insulin cause an autosomal-dominant syndrome of di

52 INS-1res cells with a plasmid containing the human insulin cDNA and expansion of the transfected colo

53 the liver-specific albumin promoter, and the human insulin cDNA modified for furin cleavage compatibi

54 Four lines of transgenic mice harboring a human insulin cDNA with expression driven by the goat be

55 this represents the most efficient route of human insulin chemical synthesis reported to date.

56 ls, is processed and stored as CpepSfGFP and human insulin comprising only approximately 0.04% of tot

57 lin infusion (group 3) achieved steady-state human insulin concentrations of 22,000 plus minus 1,800

58 infusion (group 2) established steady-state human insulin concentrations of 6,300 plus minus 510 pmo

59 nstant whether in the absence or presence of human insulin concentrations sufficient to saturate the

60 is structure leads to a model for fibrils of human insulin consistent with electron microscopic, x-ra

61 trix protease Ste23 in yeast, a homologue of human insulin-degrading enzyme, which is required for ef

62 Susceptibility to murine and human insulin-dependent diabetes mellitus correlates str

63 ese diabetic mice are a well-known model for human insulin-dependent diabetes mellitus.

64 Fish and human insulin differ by two amino acids in the critical

65 We apply our protocol to the human insulin dimer (hIns2) as a test case.

66 For example, porcine and human insulin do not stimulate Abs in C57BL/6 mice becau

67 of 3 mm glucose, exogenously added bovine or human insulin do not stimulate endogenous insulin secret

68 In humans, insulin down-regulates the expression of certain

69 adapted an existing commercial kit (Mercodia Human Insulin ELISA, 10-1113-01) to quantify insulin fro

70 The use of ins-asp rather than human insulin enabled us to disentangle exogenous and en

71 ten lack characteristic sequence features of human insulin essential for its folding, structure, and

72 t study, we investigated the contribution to human insulin expression of the GG2 motif found between

73 Analysis of overlapping peptides from human insulin found that insulin B(1-15) bound well to D

74 by the atypical responses of T cells to the human insulin fragment that are described by Kent et al.

75 rmined the cleavage sites and composition of human insulin fragments generated by human IDE.

76 oligonucleotide was demonstrated to capture human insulin from standard solutions and from nuclear e

77 lets by measuring changes in glucose-induced human insulin gene (INS) expression using a single islet

78 em repeats (VNTR) is located upstream of the human insulin gene and correlates with the incidence of

79 uence in the promoter region upstream of the human insulin gene and is widely recognized as a locus o

80 chanism of transcriptional regulation of the human insulin gene by cyclic AMP response element modula

81 engineered to contain multiple copies of the human insulin gene exhibit a large increase in insulin c

82 that AIRE mutation could specifically affect human insulin gene expression in thymic epithelial cells

83 We report 10 heterozygous mutations in the human insulin gene in 16 probands with neonatal diabetes

84 ulin-linked polymorphic region (ILPR) of the human insulin gene promoter region is reported.

85 PDX-1, which binds to four sites within the human insulin gene promoter.

86 nstrate a critical role for the Z element in human insulin gene transcription and its regulation by g

87 was to characterize the effects of FK506 on human insulin gene transcription, insulin mRNA levels, a

88 more reliable reflection of acute changes to human insulin gene transcriptional rates and that glucos

89 ontrolled by the 5' regulatory region of the human insulin gene was decreased in late passage betaTC-

90 A human insulin gene was engineered to allow normal proces

91 an influence transcriptional activity of the human insulin gene, and thus, may contribute to that por

92 llite, located in the promoter region of the human insulin gene, comprises a variable number of tande

93 cells with lentivirus carrying an additional human insulin gene-enhanced secretion twofold.

94 motif, is a site for PDX-1 activation in the human insulin gene.

95 AG4TGTG4/TGTC4ACAC4) located upstream of the human insulin gene.

96 the promoter sequence was isolated from the human insulin gene.

97 ', is located 363 base-pairs upstream of the human insulin gene.

98 ion with the transcriptional activity of the human insulin gene.

99 sfection with combinations of genes encoding human insulin, GLUT2, and glucokinase.

100 cutaneously, [N(epsilon)-palmitoyl Lys(B29)] human insulin had a longer duration of action; a flatter

101 The availability of a DNA ligand to human insulin has analytical importance as well, offerin

102 ated insulin [Lys(B29)-lithocholyl des-(B30) human insulin] has been crystallized and the structure d

103 Although several analogs of human insulin have been developed, the currently prescri

104 minal prolyl and lysyl residues of wild-type human insulin have been inverted, can be crystallized in

105 The structure and dynamics of the R6 human insulin hexamer are investigated by two- and three

106 oach in mapping of disulfide bonds of intact human insulin (HI) and lysozyme.

107 The effects of recombinant human insulin (HI) delivered intraportally or peripheral

108 TKs found in nature, we have transformed the human insulin (hIR) and hepatocyte growth factor recepto

109 in vivo by measuring circulating glucose and human insulin; however, it will be important to recover

110 om C57BL/6 mice primed with either bovine or human insulin in CFA.

111 d insulin analogues were similar to premixed human insulin in decreasing fasting glucose levels, hemo

112 emonstrate T cell proliferative responses to human insulin in IDDM patients.

113 We compared insulin lispro and regular human insulin in the mealtime treatment of 1,008 patient

114 s patient convenience, compared with regular human insulin, in IDDM patients.

115 In group 3 (n = 4), the human insulin infusion was increased to a saturating dos

116 ct injection of PIP peptides 640 or 250 with human insulin into the lumen of rat jejunum caused a dec

117 Furthermore, these cells secrete human insulin into the serum of mice shortly after trans

118 Human insulin is a pivotal protein hormone controlling m

119 Selective capture and release of human insulin is verified using matrix-assisted laser de

120 engineered monomer ([AspB10, LysB28, ProB29]-human insulin) is determined at neutral pH as a template

121 NN304 [Lys(B29)-tetradecanoyl des(B30) human insulin] is a potentially therapeutic insulin anal

122 Insulin lispro [Lys (B28), Pro (B29) human insulin] is a rapidly absorbed analog that has dim

123 ecline in NN304 clearance from plasma as the human insulin level increased (P < 0.05 by ANOVA).

124 nged in the absence and presence of elevated human insulin levels (12.6 plus minus 1.2 vs. 12.4 plus

125 M/islets exhibited euglycemia and detectable human insulin levels (157 muU/mL), whereas no human insu

126 304 concentrations also rose with increasing human insulin levels but did not achieve significance in

127 ke peptide in cone-snail venom with moderate human insulin-like bioactivity.

128 Human insulin-like growth factor (IGF)-II mRNA has been

129 Mouse models suggest that recombinant human insulin-like growth factor 1 (IGF-1) (rhIGF1) (mec

130 Transgenic mice expressing human insulin-like growth factor 1 (IGF-1) in basal epit

131 Human insulin-like growth factor 1 (IGF-1) is a 70 amino

132 sgenic mice expressing a mutated form of the human insulin-like growth factor 1 receptor (IGF-1R) in

133 The human insulin-like growth factor 2 (IGF2) and insulin ge

134 ture of a metastable folding intermediate of human insulin-like growth factor I (IGF-I) and an engine

135 ntinuous intravenous infusion of recombinant human insulin-like growth factor I (rhIGF-I).

136 Commercial preparations of recombinant human insulin-like growth factor I became available in 2

137 es in the cytoplasmic domain of an oncogenic human insulin-like growth factor I receptor (gag-IGFR) w

138 en developed which binds specifically to the human insulin-like growth factor I receptor (IGF-IR) and

139 domains of the Drosophila insulin receptor, human insulin-like growth factor I receptor, and human i

140 dequate delivery of administered recombinant human insulin-like growth factor I to other tissues, inc

141 Human insulin-like growth factor II gene (IGF2) is overe

142 The human insulin-like growth factor II gene is regulated in

143 The two contiguous IGF2 (human insulin-like growth factor II) and H19 genes are r

144 To improve delivery of human insulin-like growth factor-1 (hIGF-1) to brain and

145 e reported to have resistance to recombinant human insulin-like growth factor-1 (rhIGF-1).

146 tudy, we used transgenic mice overexpressing human insulin-like growth factor-1 exclusively in skelet

147 Treatment with recombinant human insulin-like growth factor-1 restores responses of

148 d accumulation (up to 5.8 fold; P < 0.05) of human insulin-like growth factor-binding protein-3 in mo

149 mac25 propeptide shares a 20-25% identity to human insulin-like growth factor-binding proteins (IGFBP

150 ne encoding a dominant-negative, kinase-dead human insulin-like growth factor-I receptor (IGF-IR) tha

151 ccur following administration of recombinant human insulin-like growth factor-I to the intact animal.

152 Human insulin-like growth factors I and II (hIGF-I, hIGF

153 uence and structural homology between mature human insulin-like growth factors IGF-1 and IGF-2 makes

154 In contrast to exogenously administered human insulin, LY demonstrated preferential hepatic effe

155 Lower-cost human insulin may be effective for many patients with ty

156 ibe an alternative open reading frame within human insulin mRNA encoding a highly immunogenic polypep

157 les consistently showed the highest level of human insulin mRNA expression and luciferase protein exp

158 kinetics of fibril formation of 20 different human insulin mutants at both low pH (conditions favorin

159 Dogs received 0.36 units/kg s.c. regular human insulin (n = 6) or 1 mg (2.8 units/kg) or 2 mg (5.

160 NN304 (or human insulin) (n = 6 each) was infused at 10.2 pmol cen

161 e that hyperglycaemia impairs the actions of human insulin on umbilical vein endothelial cells isolat

162 ets contained human cells that colabeled for human insulin or PDX-1.

163 and 38 from other sources) if they involved human insulins or insulin analogues, were at least 4 wee

164 ulin analog Lys(B29)-tetradecanoyl des-(B30) human insulin, or NN304, as a marker for insulin transpo

165 sulin were readily differentiated, including human insulin (P28K29) and Lispro insulin (K28P29), whic

166 Cooling of preheated human insulin-poly(ethylene glycol)-water solutions resu

167 We examined the plasticity of human insulin-producing beta-cells in a model of islet c

168 ovision of an unlimited source of functional human insulin-producing cells and 2) prevention of rejec

169 ls, thereby providing an unlimited source of human insulin-producing cells for basic biochemical stud

170 a well-characterized and unlimited source of human insulin-producing cells.

171 mice express SOCS-1 under the control of the human insulin promoter and are on the C57BL6/J backgroun

172 ingly, while Pdx1 responsive elements in the human insulin promoter conform to the pentanucleotide 5'

173 ere observed in transgenic mice containing a human insulin promoter fragment, pointing to the respons

174 does not explain all of the activity of the human insulin promoter in cultured islets, and other tra

175 transfected into primary islet cultures, the human insulin promoter is activated by glucose.

176 Site-directed mutations of the human insulin promoter mapped the low-potency PARP inhib

177 ment between base pairs -341 and -260 of the human insulin promoter, the same region in which a trans

178 n and substitution mutations of the proximal human insulin promoter, we mapped a metabolic response e

179 FK506 decreased HIT cell expression of the human insulin promoter-CAT reporter gene by 40% in the p

180 ncreatic beta cells under the control of the human insulin promoter.

181 thiazine antipsychotics as modulators of the human insulin promoter.

182 32D myeloid progenitor cells containing the human insulin receptor (32D(IR)).

183 cted with an expression plasmid encoding the human insulin receptor (CHO/HIRc) at concentrations wher

184 overexpression of a dominant-negative mutant human insulin receptor (ESMIRO).

185 levels of native and misfolded forms of the human insulin receptor (hIR) and a human variant found i

186 vectors that the 5'-UTR of the mRNA encoding human insulin receptor (hIR) contains a functional IRES.

187 The cytoplasmic juxtamembrane domain of the human insulin receptor (hIR) contains a single copy of t

188 the folding, assembly, and transport of the human insulin receptor (HIR), a dimeric RTK.

189 imeric monoclonal antibody (MAb) against the human insulin receptor (HIR).

190 t is a monoclonal antibody (MAb) against the human insulin receptor (HIR).

191 starved rat-1 fibroblasts overexpressing the human insulin receptor (HIRc cells) in vivo.

192 rat fibroblast cell line overexpressing the human insulin receptor (HIRc-B), SHIP inhibited membrane

193 Rat1 fibroblasts transfected with wild-type human insulin receptor (HIRcB) and a truncated receptor

194 ial cell (EC)-specific overexpression of the human insulin receptor (hIRECO) using the Tie2 promoter-

195 TMD and intracellular domain of the soluble human insulin receptor (HIRs) with constant domains from

196 eated rat hepatic tumor cell line expressing human insulin receptor (HTC-IR) and livers from lean and

197 covalently to the cytoplasmic domain of the human insulin receptor (IR) beta-subunit when cells are

198 s, we have coexpressed the human IRR and the human insulin receptor (IR) in NIH-3T3 cells.

199 81, compound 1), which induced activation of human insulin receptor (IR) tyrosine kinase and mediated

200 these chimeric RTKs, termed light-controlled human insulin receptor (LihIR) and light-controlled huma

201 f Chinese hamster ovary cells expressing the human insulin receptor and differentiated 3T3L1 adipocyt

202 imulated tyrosine autophosphorylation of the human insulin receptor and hDIR, and both receptors medi

203 ptor binding to CHO-T cells transfected with human insulin receptor and in vivo metabolic clearance r

204 n Chinese hamster ovary cells expressing the human insulin receptor and murine 3T3L1 adipocytes, insu

205 CHO cells overexpressing the human insulin receptor and rat IRS1 were stimulated with

206 screened with the cytoplasmic domain of the human insulin receptor as bait.

207 he function of a chimeric DIR containing the human insulin receptor binding domain (hDIR) was investi

208 This extension is absent from the human insulin receptor but resembles a region in insulin

209 tations in the tyrosine kinase domain of the human insulin receptor frequently result in a dominantly

210 of-function mutations in both alleles of the human insulin receptor gene (INSR) cause extreme insulin

211 a subunits in the (alpha beta)2 dimer of the human insulin receptor have been identified by labeling

212 he affinity of N-lithocholyl insulin for the human insulin receptor is not significantly diminished.

213 In contrast, transfection of malfunctioning human insulin receptor mutants, identified originally fr

214 f Chinese hamster ovary cells expressing the human insulin receptor resulted in a time-dependent decr

215 A resolution of an amino-terminal segment of human insulin receptor substrate 1 that encompasses its

216 ry with phosphorylated baculovirus- produced human insulin receptor substrate 1.

217 The human insulin receptor substrate-1 (hIRS-1) is a key int

218 The most commonly detected polymorphism in human insulin receptor substrate-1 (IRS-1), a glycine to

219 IRS-1 was required by the human insulin receptor to activate PI 3-kinase and p70s6

220 for their abilities to selectively activate human insulin receptor tyrosine kinase (IRTK).

221 screen for small molecules that activate the human insulin receptor tyrosine kinase, a nonpeptidyl fu

222 ucture of the purified, functionally active, human insulin receptor using negative stain and cryo-ele

223 r, we incubated CHO cells overexpressing the human insulin receptor with an antibody to the extracell

224 n Chinese hamster ovary cells expressing the human insulin receptor, both proteins display a diffuse,

225 sis was evaluated directly using recombinant human insulin receptor, hamster beta 2-adrenergic recept

226 n Chinese hamster ovary cells expressing the human insulin receptor, insulin causes decreased phospho

227 hamster ovary cells expressing the wild-type human insulin receptor, mock-transfected cells, cells ex

228 ock MA20 binding to its natural antigen, the human insulin receptor, on lymphocytes.

229 g the cytoplasmic kinase domain (CKD) of the human insulin receptor, we demonstrate that autophosphor

230 f the 83-14 monoclonal antibody (mAb) to the human insulin receptor, which is tagged with streptavidi

231 n insulin-like growth factor I receptor, and human insulin receptor-related receptor.

232 on by insulin in NIH3T3 cells overexpressing human insulin receptor.

233 terminants, INS-6 binds to and activates the human insulin receptor.

234 sequences, yet all bind to and activate the human insulin receptor.

235 on in NIH-3T3 fibroblasts overexpressing the human insulin receptor.

236 transmembrane and cytoplasmic domains of the human insulin receptor.

237 ciation of a serine kinase activity with the human insulin receptor.

238 R, a fibroblast cell line overexpressing the human insulin receptor.

239 sine phosphorylated in vitro by the isolated human insulin receptor.

240 address this, we adopted a strategy to model human insulin receptoropathy in mice, using Cre recombin

241 ovary (CHO) cells that overexpress wild-type human insulin receptors (CHO-hIR-WT) or mutant insulin r

242 hamster ovary (CHO) cells overexpressing the human insulin receptors (CHO/HIRc cells).

243 from Chinese hamster ovary cells expressing human insulin receptors (CHO/IR).

244 CHO cells expressing the human insulin receptors (IR) were used to evaluate the e

245 inese hamster ovary (CHO-T) cells expressing human insulin receptors and COS-1 cells in response to i

246 inese hamster ovary cells (CHO-T) expressing human insulin receptors causes an 8-10-fold increase in

247 Rat-1 fibroblasts that overexpresses normal human insulin receptors, binding of the GTP analogue GTP

248 oporation into Rat1 fibroblasts that express human insulin receptors.

249 reover, the CTL primed with either bovine or human insulin recognize an A-chain peptide that is ident

250 Human insulin reduced the elevated rates of L-arginine t

251 d the contribution of variation in SORCS1 to human insulin-related traits in two distinct Mexican-Ame

252 Three novel human insulin-releasing cell lines designated 1.1B4, 1.4

253 amide, or PD128763 increased expression of a human insulin reporter gene suppressed by elevated gluco

254 ation in two complementary in vivo models of human insulin resistance (endothelial specific and whole

255 ously hypertensive (SHRSP) rat is a model of human insulin resistance and is characterized by reduced

256 abolic and signaling changes associated with human insulin resistance and provides a genetically amen

257 Based on these data, we propose that human insulin resistance involves a defect in GLUT4 traf

258 Identifying markers of human insulin resistance may permit development of new a

259 icate resistin in the pathophysiology of the human insulin resistance syndrome, an effect mediated by

260 y hypertensive rat (SHR) is a model of these human insulin resistance syndromes.

261 m by which TNF may play an important role in human insulin resistance.

262 The human insulin-resistance syndromes, type 2 diabetes, obe

263 and may be important in the pathogenesis of human insulin-resistance syndromes.

264 r the treatment of type 2 diabetes and other human insulin-resistant states in the future.

265 ve potential to differentially influence the human insulin response.

266 Overexpression of human insulin-responsive aminopeptidase/oxytocinase resc

267 Overexpression of SOX4 in the human insulin-secreting cell EndoC-betaH2 interfered wit

268 NES2Y is a proliferating human insulin-secreting cell line that we have derived f

269 excess glucose or lipid influence mouse and human insulin secretion and beta cell activity and show

270 In humans, insulin sensitivity varies according to time of

271 ices to evaluate their propensity to deliver human insulin solutions to the nasal cavity for redistri

272 o the differential sensitivity of bovine and human insulin-specific CD4+ T cells.

273 ific CD4(+)T cells and demonstrate efficient human insulin-specific Foxp3(+)Treg-induction upon subim

274 In humans, insulin-stimulated PAK activation was decreased

275 response to [N(epsilon)-palmitoyl Lys(B29)] human insulin support the development and further testin

276 Further, human insulin suppressed mosquito immunity through susta

277 tal composition comprising 75% C8-HI and 25% human insulin that exhibits near-ideal basal pharmacodyn

278 s less with insulin lispro than with regular human insulin therapy during three of four quarters of t

279 ined by direct gene fusion of a single-chain human insulin to human serum albumin.

280 ting analog, [N(epsilon)-palmitoyl Lys(B29)] human insulin, to serum albumin in vitro, and the time a

281 addition of 100 nm bovine insulin or 500 nm human insulin together with 3 mm glucose had no stimulat

282 Overexpression of ins-1, or expression of human insulin under the control of ins-1 regulatory sequ

283 e used to extend the time action of insulin, human insulin was acylated at the epsilon-amino group of

284 Human insulin was administered to 13 beagles via inhalat

285 involved switching patients from analogue to human insulin was associated with a small increase in po

286 uman insulin levels (157 muU/mL), whereas no human insulin was detected in the islet-only transplanta

287 Regular human insulin was infused (0.28 pmol x m(-2) x min(-1))

288 In group 2 (n = 6), starting at time 0, human insulin was infused at a pharmacologic dose (60 pm

289 ted immediately before the meal, and regular human insulin was injected 30-45 min before the meal.

290 The mass transfer kinetics of human insulin was investigated on a 50 mm x 2.1 mm colum

291 In addition, human insulin was not detected in the serum of SCID-hu m

292 s compared with untreated diabetic mice, but human insulin was not detected.

293 n for the anti-relaxin antibody, whereas the human insulin was transformed into a bona fide relaxin.

294 nous glucose production (EGP) in nondiabetic humans, insulin was infused at rates of 0.25, 0.375, or

295 proteolytic processing to CpepGFP and native human insulin, which are specifically detected and cosec

296 Human insulin, which consists of disulfide cross-linked

297 ne Hagedorn) crystalline complex formed with human insulin, which is commonly used as the long-acting

298 enhancement to the biophysical stability of human insulin while maintaining its potency.

299 The new route affords human insulin with a yield of 68 % based on the starting

300 ether the isolated A and B chain peptides of human insulin would form fibrils at neutral and acidic p